148 related articles for article (PubMed ID: 31250767)
1. The Perplexity of Synergistic Duality: Inter-molecular Mechanisms of Communication in BCR-ABL1.
Elrashedy AA; Ramharack P; Soliman MES
Anticancer Agents Med Chem; 2019; 19(13):1642-1650. PubMed ID: 31250767
[TBL] [Abstract][Full Text] [Related]
2. A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance.
El Rashedy AA; Appiah-Kubi P; Soliman MES
Protein J; 2019 Apr; 38(2):142-150. PubMed ID: 30877503
[TBL] [Abstract][Full Text] [Related]
3. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
[TBL] [Abstract][Full Text] [Related]
4. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Manley PW; Barys L; Cowan-Jacob SW
Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
[TBL] [Abstract][Full Text] [Related]
5. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Wylie AA; Schoepfer J; Jahnke W; Cowan-Jacob SW; Loo A; Furet P; Marzinzik AL; Pelle X; Donovan J; Zhu W; Buonamici S; Hassan AQ; Lombardo F; Iyer V; Palmer M; Berellini G; Dodd S; Thohan S; Bitter H; Branford S; Ross DM; Hughes TP; Petruzzelli L; Vanasse KG; Warmuth M; Hofmann F; Keen NJ; Sellers WR
Nature; 2017 Mar; 543(7647):733-737. PubMed ID: 28329763
[TBL] [Abstract][Full Text] [Related]
6. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
[TBL] [Abstract][Full Text] [Related]
7. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
Zhan JY; Ma J; Zheng QC
J Mol Graph Model; 2019 Jun; 89():242-249. PubMed ID: 30927708
[TBL] [Abstract][Full Text] [Related]
10. A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.
Manley PW; Huth F; Moussaoui S; Schoepfer J
Bioorg Med Chem Lett; 2022 Mar; 59():128577. PubMed ID: 35065232
[TBL] [Abstract][Full Text] [Related]
11. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
El Rashedy AA; Olotu FA; Soliman MES
Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229
[TBL] [Abstract][Full Text] [Related]
12. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D; Hughes TP
Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
[TBL] [Abstract][Full Text] [Related]
13. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
14. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Qiang W; Antelope O; Zabriskie MS; Pomicter AD; Vellore NA; Szankasi P; Rea D; Cayuela JM; Kelley TW; Deininger MW; O'Hare T
Leukemia; 2017 Dec; 31(12):2844-2847. PubMed ID: 28819281
[No Abstract] [Full Text] [Related]
18. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.
G Lindström HJ; Friedman R
BMC Cancer; 2020 May; 20(1):397. PubMed ID: 32380976
[TBL] [Abstract][Full Text] [Related]
19. Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Yang Y; Gao H; Sun X; Sun Y; Qiu Y; Weng Q; Rao Y
J Med Chem; 2020 Aug; 63(15):8567-8583. PubMed ID: 32657579
[TBL] [Abstract][Full Text] [Related]
20. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]